PMEL and neoplasm: Additional studies are necessary to address whether the chitosan may be used to deliver both siRNA therapeutic and protein-based chaperone vaccine, and whether this antibody responses to gp100 also contributes to tumor suppression resulting from the combinatorial immunotherapy.